vs

Side-by-side financial comparison of Fortress Biotech, Inc. (FBIO) and USCB FINANCIAL HOLDINGS, INC. (USCB). Click either name above to swap in a different company.

USCB FINANCIAL HOLDINGS, INC. is the larger business by last-quarter revenue ($22.2M vs $16.1M, roughly 1.4× Fortress Biotech, Inc.). USCB FINANCIAL HOLDINGS, INC. runs the higher net margin — 6.1% vs -24.5%, a 30.6% gap on every dollar of revenue. On growth, USCB FINANCIAL HOLDINGS, INC. posted the faster year-over-year revenue change (14.7% vs 6.3%). Over the past eight quarters, USCB FINANCIAL HOLDINGS, INC.'s revenue compounded faster (12.3% CAGR vs 11.0%).

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

USCB Financial Holdings, Inc. is a U.S.-headquartered bank holding company that offers comprehensive retail and commercial banking services, including deposit products, personal and business loans, wealth management, and digital banking tools. It primarily serves individual consumers, small and medium-sized enterprises, and local corporate clients across its operating regions in the United States, prioritizing personalized customer experiences and community-oriented financial services.

FBIO vs USCB — Head-to-Head

Bigger by revenue
USCB
USCB
1.4× larger
USCB
$22.2M
$16.1M
FBIO
Growing faster (revenue YoY)
USCB
USCB
+8.5% gap
USCB
14.7%
6.3%
FBIO
Higher net margin
USCB
USCB
30.6% more per $
USCB
6.1%
-24.5%
FBIO
Faster 2-yr revenue CAGR
USCB
USCB
Annualised
USCB
12.3%
11.0%
FBIO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
FBIO
FBIO
USCB
USCB
Revenue
$16.1M
$22.2M
Net Profit
$-3.9M
$1.4M
Gross Margin
66.1%
Operating Margin
-28.8%
14.7%
Net Margin
-24.5%
6.1%
Revenue YoY
6.3%
14.7%
Net Profit YoY
41.8%
-80.3%
EPS (diluted)
$-0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
FBIO
FBIO
USCB
USCB
Q4 25
$16.1M
$22.2M
Q3 25
$17.6M
$25.0M
Q2 25
$16.4M
$24.4M
Q1 25
$13.1M
$22.8M
Q4 24
$15.1M
$23.0M
Q3 24
$14.6M
$21.5M
Q2 24
$14.9M
$20.5M
Q1 24
$13.0M
$17.6M
Net Profit
FBIO
FBIO
USCB
USCB
Q4 25
$-3.9M
$1.4M
Q3 25
$5.8M
$8.9M
Q2 25
$15.5M
$8.1M
Q1 25
$-10.6M
$7.7M
Q4 24
$-6.8M
$6.9M
Q3 24
$-12.9M
$6.9M
Q2 24
$-10.9M
$6.2M
Q1 24
$-15.4M
$4.6M
Gross Margin
FBIO
FBIO
USCB
USCB
Q4 25
66.1%
Q3 25
67.4%
Q2 25
69.9%
Q1 25
63.5%
Q4 24
69.1%
Q3 24
69.4%
Q2 24
61.6%
Q1 24
53.9%
Operating Margin
FBIO
FBIO
USCB
USCB
Q4 25
-28.8%
14.7%
Q3 25
-38.6%
47.3%
Q2 25
-222.2%
44.0%
Q1 25
-169.9%
44.2%
Q4 24
-158.3%
39.6%
Q3 24
-151.0%
42.5%
Q2 24
-186.5%
39.8%
Q1 24
-280.6%
34.3%
Net Margin
FBIO
FBIO
USCB
USCB
Q4 25
-24.5%
6.1%
Q3 25
33.2%
35.8%
Q2 25
94.4%
33.4%
Q1 25
-80.6%
33.5%
Q4 24
-44.7%
30.0%
Q3 24
-88.0%
32.3%
Q2 24
-73.5%
30.3%
Q1 24
-118.3%
26.2%
EPS (diluted)
FBIO
FBIO
USCB
USCB
Q4 25
$-0.15
Q3 25
$0.11
$0.45
Q2 25
$0.45
Q1 25
$-0.48
Q4 24
$-0.16
Q3 24
$-0.76
$0.35
Q2 24
$-0.73
Q1 24
$-1.04

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
FBIO
FBIO
USCB
USCB
Cash + ST InvestmentsLiquidity on hand
$79.4M
$38.5M
Total DebtLower is stronger
$52.4M
Stockholders' EquityBook value
$49.9M
$217.2M
Total Assets
$185.5M
$2.8B
Debt / EquityLower = less leverage
1.05×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
FBIO
FBIO
USCB
USCB
Q4 25
$79.4M
$38.5M
Q3 25
$86.2M
$56.8M
Q2 25
$74.4M
$54.8M
Q1 25
$91.3M
$98.0M
Q4 24
$57.3M
$77.0M
Q3 24
$58.9M
$38.5M
Q2 24
$76.2M
$77.3M
Q1 24
$83.8M
$126.5M
Total Debt
FBIO
FBIO
USCB
USCB
Q4 25
$52.4M
Q3 25
$47.8M
Q2 25
$50.0M
Q1 25
$56.4M
Q4 24
$58.0M
Q3 24
$52.5M
Q2 24
$67.0M
Q1 24
$61.4M
Stockholders' Equity
FBIO
FBIO
USCB
USCB
Q4 25
$49.9M
$217.2M
Q3 25
$55.9M
$209.1M
Q2 25
$43.9M
$231.6M
Q1 25
$22.3M
$225.1M
Q4 24
$22.7M
$215.4M
Q3 24
$21.2M
$213.9M
Q2 24
$17.9M
$201.0M
Q1 24
$23.0M
$195.0M
Total Assets
FBIO
FBIO
USCB
USCB
Q4 25
$185.5M
$2.8B
Q3 25
$181.4M
$2.8B
Q2 25
$159.9M
$2.7B
Q1 25
$178.1M
$2.7B
Q4 24
$144.2M
$2.6B
Q3 24
$127.1M
$2.5B
Q2 24
$145.7M
$2.5B
Q1 24
$164.6M
$2.5B
Debt / Equity
FBIO
FBIO
USCB
USCB
Q4 25
1.05×
Q3 25
0.86×
Q2 25
1.14×
Q1 25
2.53×
Q4 24
2.55×
Q3 24
2.48×
Q2 24
3.75×
Q1 24
2.67×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
FBIO
FBIO
USCB
USCB
Operating Cash FlowLast quarter
$-12.5M
$42.8M
Free Cash FlowOCF − Capex
$42.5M
FCF MarginFCF / Revenue
191.4%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
31.40×
TTM Free Cash FlowTrailing 4 quarters
$95.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
FBIO
FBIO
USCB
USCB
Q4 25
$-12.5M
$42.8M
Q3 25
$-6.1M
$20.1M
Q2 25
$-27.6M
$18.0M
Q1 25
$-19.6M
$14.6M
Q4 24
$-12.9M
$34.8M
Q3 24
$-20.1M
$11.3M
Q2 24
$-21.8M
$18.3M
Q1 24
$-25.4M
$8.1M
Free Cash Flow
FBIO
FBIO
USCB
USCB
Q4 25
$42.5M
Q3 25
$20.0M
Q2 25
$18.0M
Q1 25
$14.6M
Q4 24
$34.5M
Q3 24
$11.2M
Q2 24
$18.2M
Q1 24
$8.0M
FCF Margin
FBIO
FBIO
USCB
USCB
Q4 25
191.4%
Q3 25
80.3%
Q2 25
73.7%
Q1 25
63.9%
Q4 24
150.2%
Q3 24
52.2%
Q2 24
88.8%
Q1 24
45.4%
Capex Intensity
FBIO
FBIO
USCB
USCB
Q4 25
1.4%
Q3 25
0.5%
Q2 25
0.2%
Q1 25
0.2%
Q4 24
1.4%
Q3 24
0.0%
0.4%
Q2 24
0.4%
Q1 24
0.5%
Cash Conversion
FBIO
FBIO
USCB
USCB
Q4 25
31.40×
Q3 25
-1.04×
2.25×
Q2 25
-1.78×
2.22×
Q1 25
1.91×
Q4 24
5.05×
Q3 24
1.63×
Q2 24
2.95×
Q1 24
1.75×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons